TORONTO, June 19, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced that it will seek regulatory guidance from the U.S.

TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro-Technics in Scarborough, Ontario to complete the preclinical toxicology and pharmacology studies to support an Investigational New Drug (IND) application for Metablok, the Company’s drug candidate for preventing acute kidney injury.

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, announced that the Company’s common shares have been approved to begin trading today on the OTCQB Venture Market (OTCQB) under the ticker ACHFF.